<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Hites, Maya</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Standard Dosage Regimens of Broad-Spectrum β-Lactams are Inadequate to Treat “Difficult-to-Treat” Pathogens in Obese Noncritically Ill Patients</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">28-28</style></pages><abstract><style  face="normal" font="default" size="100%">Results of a large case series of broad spectrum β-lactam agents in obese noncritically ill patients with infection treated using standard dose regimens showed insufficient measured serum concentrations to treat difficult-to-treat pathogens. This article presents a poster [Hites et al. ICAAC 2012 a-637] that suggested altered pharmacokinetics in obese patients may be responsible.</style></abstract><number><style face="normal" font="default" size="100%">14</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>